
AMX0035 Continues to Stabilize and Improve Wolfram Syndrome at 48 Weeks, Phase 2 HELIOS Trial Shows
Newly announced 48-week data from the phase 2 HELIOS trial (NCT05676043), an open-label study of AMX0035 (Amylyx Pharmaceuticals) in patients with Wolfram syndrome, revealed that the agent was safe, and resulted in sustained improvements or stabilization …